Skip to main content
Erschienen in: World Journal of Surgery 5/2008

01.05.2008

Surgery and Radiofrequency Ablation for Treatment of Liver Metastases from Midgut and Foregut Carcinoids and Endocrine Pancreatic Tumors

verfasst von: John Eriksson, Peter Stålberg, Anders Nilsson, Johan Krause, Christina Lundberg, Britt Skogseid, Dan Granberg, Barbro Eriksson, Göran Åkerström, Per Hellman

Erschienen in: World Journal of Surgery | Ausgabe 5/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

Many neuroendocrine tumors (NETs) have a tendency to metastasize to the liver. In case of limited number of metastases, liver surgery or radiofrequency ablation (RFA) may result in apparently total clearance of metastases. However, it is not clear whether such therapy will provide symptom reduction or increased survival.

Methods

Seventy-three patients with foregut (n = 6) or midgut carcinoids (n = 37) or endocrine pancreatic tumors (n = 28), and two patients with NETs without discernable origin were studied. Symptoms were evaluated using a Symptom Severity Score. Liver surgery was performed in 42 operations and RFA on 205 lesions.

Results

Apparently total clearance of liver metastases was attained in 1 of 6 patients with foregut carcinoids, 15 of 37 with midgut carcinoids, and 13 of 28 with EPT. Symptom improvement was noted in 12 of 17 (70.6%) patients with carcinoid syndrome, and 75% also reduced their 5-HIAA and P-CgA by at least 50%. Patients with nonfunctioning EPT generally had no improvement of symptoms after surgical/RFA liver treatment, but eight patients had functioning EPT, and four of these reduced their biochemical markers by at least 50%. NETs with higher Ki67 index tended to recur more often. Complications occurred in 9 of 45 open surgery procedures, and in 8 of 203 RFA procedures.

Conclusions

Treatment of liver metastases is successful in midgut carcinoid patients with limited liver metastases. Patients with foregut carcinoid and EPTs recur more often, possibly related to higher Ki67 index, and treatment of liver lesions less often reduces symptoms. Liver resections and RFA may be safely performed, and RFA is associated with few complications.
Literatur
1.
Zurück zum Zitat Solcia G, Kloppel G, Sobin L (2000) Histological typing of endocrine tumors. Springer-Verlag, New York Solcia G, Kloppel G, Sobin L (2000) Histological typing of endocrine tumors. Springer-Verlag, New York
2.
Zurück zum Zitat Hellman P, Lundstrom T, Ohrvall U et al (2002) Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 26:991–997PubMedCrossRef Hellman P, Lundstrom T, Ohrvall U et al (2002) Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 26:991–997PubMedCrossRef
3.
Zurück zum Zitat Hellman P, Ladjevardi S, Skogseid B et al (2002) Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg 26:1052–1056PubMedCrossRef Hellman P, Ladjevardi S, Skogseid B et al (2002) Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg 26:1052–1056PubMedCrossRef
4.
Zurück zum Zitat de Vries H, Verschueren RC, Willemse PH et al (2002) Diagnostic, surgical and medical aspect of the midgut carcinoids. Cancer Treat Rev 28:11–25PubMedCrossRef de Vries H, Verschueren RC, Willemse PH et al (2002) Diagnostic, surgical and medical aspect of the midgut carcinoids. Cancer Treat Rev 28:11–25PubMedCrossRef
5.
Zurück zum Zitat Öberg K (2003) Carcinoid tumors, carcinoid syndrome and related disorders. In: Larsen PR, Kronenberg HM, Melmed S et al eds (2003) Williams textbook of endocrinology. WB Saunders, Philadelphia, pp 1857–1876 Öberg K (2003) Carcinoid tumors, carcinoid syndrome and related disorders. In: Larsen PR, Kronenberg HM, Melmed S et al eds (2003) Williams textbook of endocrinology. WB Saunders, Philadelphia, pp 1857–1876
6.
Zurück zum Zitat Schell S, Ramsay Camp E, Caridi JG et al (2002) Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors. J Gastrointest Surg 6:664–670PubMedCrossRef Schell S, Ramsay Camp E, Caridi JG et al (2002) Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors. J Gastrointest Surg 6:664–670PubMedCrossRef
7.
Zurück zum Zitat Benevento A, Boni L, Frediani L et al (2000) Result of liver resection as treatment for metastases from noncolorectal cancer. J Surg Oncol 74:24–29PubMedCrossRef Benevento A, Boni L, Frediani L et al (2000) Result of liver resection as treatment for metastases from noncolorectal cancer. J Surg Oncol 74:24–29PubMedCrossRef
8.
Zurück zum Zitat Åkerström G, Hellman P (2007) Surgery on neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab 21:87–109PubMedCrossRef Åkerström G, Hellman P (2007) Surgery on neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab 21:87–109PubMedCrossRef
9.
Zurück zum Zitat Elias D, Lasser P, Ducreux M et al (2003) Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single-center prospective study. Surgery 133:375–382PubMedCrossRef Elias D, Lasser P, Ducreux M et al (2003) Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single-center prospective study. Surgery 133:375–382PubMedCrossRef
10.
Zurück zum Zitat Söreide O, Berstad T, Bakka A et al (1992) Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors. Surgery 111:48–54PubMed Söreide O, Berstad T, Bakka A et al (1992) Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors. Surgery 111:48–54PubMed
11.
Zurück zum Zitat Wängberg B, Westberg G, Tylén U et al (1996) Survival of patients with liver metastases from carcinoid tumors after aggressive tumor reduction. World J Surg 20:892–899PubMedCrossRef Wängberg B, Westberg G, Tylén U et al (1996) Survival of patients with liver metastases from carcinoid tumors after aggressive tumor reduction. World J Surg 20:892–899PubMedCrossRef
12.
Zurück zum Zitat Oberg K, Eriksson B (2005) Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 19:753–781PubMedCrossRef Oberg K, Eriksson B (2005) Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 19:753–781PubMedCrossRef
13.
Zurück zum Zitat Norton JA, Warren RS, Kelly MG et al (2003) Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 134:1057–1063PubMedCrossRef Norton JA, Warren RS, Kelly MG et al (2003) Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 134:1057–1063PubMedCrossRef
14.
Zurück zum Zitat Chamberlain R, Canes D, K B et al (2000) Does intervention alter outcomes? J Am Coll Surg 190:432–445 Chamberlain R, Canes D, K B et al (2000) Does intervention alter outcomes? J Am Coll Surg 190:432–445
15.
Zurück zum Zitat Sarmiento J, Heywood G, Rubin J et al (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197:29–37PubMedCrossRef Sarmiento J, Heywood G, Rubin J et al (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197:29–37PubMedCrossRef
16.
Zurück zum Zitat Zar N, Garmo H, Holmberg L et al (2004) Long-term survival of patients with small intestinal carcinoid tumors. World J Surg 28:1163–1168PubMedCrossRef Zar N, Garmo H, Holmberg L et al (2004) Long-term survival of patients with small intestinal carcinoid tumors. World J Surg 28:1163–1168PubMedCrossRef
17.
Zurück zum Zitat Elvin A, Skogseid B, Hellman P (2005) Radiofrequency ablation of neuroendocrine liver metastases. Abdom Imaging 30:427–434PubMedCrossRef Elvin A, Skogseid B, Hellman P (2005) Radiofrequency ablation of neuroendocrine liver metastases. Abdom Imaging 30:427–434PubMedCrossRef
18.
Zurück zum Zitat Atwell T, Charboneau J, Que F et al (2005) Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. Cardiovasc Intervent Radiol 28:409–421PubMedCrossRef Atwell T, Charboneau J, Que F et al (2005) Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. Cardiovasc Intervent Radiol 28:409–421PubMedCrossRef
19.
Zurück zum Zitat Mazzaglia PJ, Berber E, Milas M et al (2007) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 142:10–19PubMedCrossRef Mazzaglia PJ, Berber E, Milas M et al (2007) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 142:10–19PubMedCrossRef
20.
Zurück zum Zitat Cunningham J, Grimelius L, Sundin A et al (2007) Malignant ileocecal serotonin producing carcinoid tumors: the presence of broad cells-band growth pattern and/or Ki67 index >1% identifies patients with worse prognosis. Acta Oncol 46:747–756PubMedCrossRef Cunningham J, Grimelius L, Sundin A et al (2007) Malignant ileocecal serotonin producing carcinoid tumors: the presence of broad cells-band growth pattern and/or Ki67 index >1% identifies patients with worse prognosis. Acta Oncol 46:747–756PubMedCrossRef
21.
Zurück zum Zitat Ahlman H, Westberg G, Wängberg B et al (1996) Treatment of liver metastases of carcinoid tumors World J Surg 20:196–202PubMedCrossRef Ahlman H, Westberg G, Wängberg B et al (1996) Treatment of liver metastases of carcinoid tumors World J Surg 20:196–202PubMedCrossRef
22.
Zurück zum Zitat de Herder WW, Lamberts SW (2003) Somatostatin analog therapy in treatment of gastrointestinal disorders and tumors. Endocrine 20:285–290PubMedCrossRef de Herder WW, Lamberts SW (2003) Somatostatin analog therapy in treatment of gastrointestinal disorders and tumors. Endocrine 20:285–290PubMedCrossRef
23.
Zurück zum Zitat Curley SAM, P, Beaty K, Ellis LM et al (2004) Early and late complications after radiofrequency ablation of malignant liver tumors n 608 patients. Ann Surg 239:450–458 Curley SAM, P, Beaty K, Ellis LM et al (2004) Early and late complications after radiofrequency ablation of malignant liver tumors n 608 patients. Ann Surg 239:450–458
24.
Zurück zum Zitat Fendrich V, Langer P, Celik I et al (2006) An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg 244:845–851PubMedCrossRef Fendrich V, Langer P, Celik I et al (2006) An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg 244:845–851PubMedCrossRef
25.
Zurück zum Zitat Schumacher G, Eisele R, Spinelli A et al (2006) The surgical approach for radiofrequency ablation of liver tumors. Recent Results Cancer Res 167:53–68PubMed Schumacher G, Eisele R, Spinelli A et al (2006) The surgical approach for radiofrequency ablation of liver tumors. Recent Results Cancer Res 167:53–68PubMed
26.
Zurück zum Zitat Adam R (2007) Developing strategies for liver metastases from colorectal cancer. Semin Oncol 34:S7–S11PubMedCrossRef Adam R (2007) Developing strategies for liver metastases from colorectal cancer. Semin Oncol 34:S7–S11PubMedCrossRef
27.
Zurück zum Zitat Sorensen SM, Mortensen FV, Nielsen DT (2007) Radiofrequency ablation of colorectal liver metastases: long-term survival Acta Radiol 48:253–258PubMedCrossRef Sorensen SM, Mortensen FV, Nielsen DT (2007) Radiofrequency ablation of colorectal liver metastases: long-term survival Acta Radiol 48:253–258PubMedCrossRef
Metadaten
Titel
Surgery and Radiofrequency Ablation for Treatment of Liver Metastases from Midgut and Foregut Carcinoids and Endocrine Pancreatic Tumors
verfasst von
John Eriksson
Peter Stålberg
Anders Nilsson
Johan Krause
Christina Lundberg
Britt Skogseid
Dan Granberg
Barbro Eriksson
Göran Åkerström
Per Hellman
Publikationsdatum
01.05.2008
Verlag
Springer-Verlag
Erschienen in
World Journal of Surgery / Ausgabe 5/2008
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-008-9510-3

Weitere Artikel der Ausgabe 5/2008

World Journal of Surgery 5/2008 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.